Anita Gokhfeld
Family · Brooklyn, NYNPI 1467107136
Payments from drug & device makers
Across 176 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$739
- E.r. Squibb & Sons, L.L.C.$516
- Daiichi Sankyo Inc.$460
- Novartis$341
- Ipsen Biopharmaceuticals, Inc$262
- AstraZeneca$226
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$301%
- Food & beverage$4,35990%
- Education$4539%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $739 |
| E.r. Squibb & Sons, L.L.C. | 24 | $516 |
| Daiichi Sankyo Inc. | 13 | $460 |
| Novartis | 22 | $341 |
| Ipsen Biopharmaceuticals, Inc | 5 | $262 |
| AstraZeneca | 6 | $226 |
| Seagen Inc. | 6 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $200 |
| Sobi, Inc | 7 | $189 |
| Gilead | 5 | $188 |
| GSK | 8 | $185 |
| Merck | 6 | $139 |
| Pharmaessentia USA Corporation | 6 | $124 |
| Incyte Corporation | 2 | $119 |
| Astellas Pharma US Inc | 5 | $107 |
| Shield Therapeutics Inc | 4 | $76 |
| Agios Pharmaceuticals, Inc. | 3 | $73 |
| Genentech USA, Inc. | 3 | $66 |
| Bayer | 3 | $63 |
| AbbVie | 3 | $60 |
| Beone Medicines USA, Inc. | 2 | $51 |
| Mirati Therapeutics, Inc. | 2 | $51 |
| Boehringer Ingelheim | 2 | $49 |
| Sanofi | 2 | $49 |
| Exelixis Inc. | 2 | $45 |
| Bristol Myers Squibb | 2 | $36 |
| Genmab U.S., Inc. | 1 | $32 |
| BD | 1 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $27 |
| Foundation Medicine, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Geron Corporation | 1 | $24 |
| Springworks Therapeutics, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,841 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 55 | $1,146,510 |
| Lenalidomide | 68 | $939,083 |
| JakafiRuxolitinib Phosphate | 67 | $927,439 |
| ImbruvicaIbrutinib | 46 | $738,742 |
| RevlimidLenalidomide | 38 | $657,209 |
| BrukinsaZanubrutinib | 43 | $604,700 |
| CalquenceAcalabrutinib Maleate | 24 | $369,565 |
| DopteletAvatrombopag Maleate | 20 | $318,386 |
| AlunbrigBrigatinib | 13 | $229,408 |
| AlecensaAlectinib Hcl | 13 | $213,145 |
| TagrissoOsimertinib Mesylate | 11 | $190,527 |
| XtandiEnzalutamide | 12 | $162,401 |
| BesremiRopeginterferon Alfa-2b-Njft | 14 | $160,324 |
| NubeqaDarolutamide | 12 | $144,062 |
| AranespDarbepoetin Alfa In Polysorbat | 52 | $137,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $516 | $1,146,51055 claims |
| Incyte CorporationJakafi | $119 | $927,43967 claims |
| Bristol Myers SquibbRevlimid | $36 | $657,20938 claims |
| AstraZenecaCalquence, Tagrisso | $226 | $560,09235 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig | $200 | $229,40813 claims |
| Genentech USA, Inc.Alecensa | $66 | $213,14513 claims |
| Astellas Pharma US IncXtandi | $107 | $162,40112 claims |
| Pharmaessentia USA CorporationBesremi | $124 | $160,32414 claims |
| BayerNubeqa | $63 | $144,06212 claims |
| Johnson & JohnsonProcrit, Xarelto | $739 | $98,40884 claims |
| AbbVieLinzess | $60 | $9,29218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.